Commentary: Dysthyroid optic neuropathy: A lurking danger in thyroid eye disease.
作者信息
Singh Manpreet, Abhaypal Khushdeep, Kaur Manpreet, Gupta Pankaj
机构信息
Department of Ophthalmology, Advanced Eye Centre, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
出版信息
Indian J Ophthalmol. 2022 Dec;70(12):4428-4429. doi: 10.4103/ijo.IJO_2126_22.
Abstract
摘要
相似文献
1
Commentary: Dysthyroid optic neuropathy: A lurking danger in thyroid eye disease.述评：甲状腺功能异常性视神经病变：甲状腺眼病中的一个潜在危险因素。
Indian J Ophthalmol. 2022 Dec;70(12):4428-4429. doi: 10.4103/ijo.IJO_2126_22.
2
Bilateral dysthyroid compressive optic neuropathy responsive to teprotumumab.对替普罗单抗有反应的双侧甲状腺功能障碍性压迫性视神经病变
Eur J Ophthalmol. 2022 May;32(3):NP46-NP49. doi: 10.1177/1120672121991042. Epub 2021 Feb 1.
3
Imaging of dysthyroid optic neuropathy.甲状腺相关眼病的影像学表现。
Eur J Ophthalmol. 2024 Sep;34(5):1346-1354. doi: 10.1177/11206721231199367. Epub 2023 Sep 6.
4
Compressive Optic Neuropathy in Thyroid Eye Disease.甲状腺眼病中的压迫性视神经病变
Int Ophthalmol Clin. 2016 Winter;56(1):51-67. doi: 10.1097/IIO.0000000000000096.
5
Optic neuropathy and diplopia from thyroid eye disease: update on pathophysiology and treatment.甲状腺眼病导致的视神经病变和复视：发病机制和治疗的最新进展。
Curr Opin Neurol. 2021 Feb 1;34(1):116-121. doi: 10.1097/WCO.0000000000000894.
6
Diagnosis and Management of Dysthyroid Optic Neuropathy.甲状腺相关眼病性视神经病变的诊断与管理
Int Ophthalmol Clin. 2023 Jul 1;63(3):233-248. doi: 10.1097/IIO.0000000000000452. Epub 2023 Jun 22.
7
Teprotumumab for Optic Neuropathy in Thyroid Eye Disease.替普罗珠单抗治疗甲状腺眼病性视神经病变
JAMA Ophthalmol. 2021 Feb 1;139(2):244-247. doi: 10.1001/jamaophthalmol.2020.5296.
8
[Efficacy of transethmoidal orbital decompression in patients with dysthyroid optic neuropathy].[经筛窦眼眶减压术治疗甲状腺相关眼病性视神经病变的疗效]
Vestn Otorinolaringol. 2020;85(6):52-55. doi: 10.17116/otorino20208506152.
9
[Ocular hypertension and optic neuropathies secondary to dysthyroid orbitopathy: Review of the literature].[甲状腺相关眼病继发的高眼压和视神经病变：文献综述]
J Fr Ophtalmol. 2021 Oct;44(8):1256-1261. doi: 10.1016/j.jfo.2021.01.026. Epub 2021 Jul 21.
10
Ocular Hypertension, Glaucoma or Compressive Neuropathy in Patient with Active TED.活动性甲状腺相关眼病患者的高眼压症、青光眼或压迫性神经病变
Folia Med (Plovdiv). 2020 Jun 30;62(2):418-423. doi: 10.3897/folmed.62.e47689.
本文引用的文献
1
Dysthyroid optic neuropathy: Demographics, risk factors, investigations, and management outcomes.甲状腺功能异常性视神经病变：人口统计学、危险因素、检查及治疗结果。
Indian J Ophthalmol. 2022 Dec;70(12):4419-4426. doi: 10.4103/ijo.IJO_719_22.
2
Diagnostic Ability of Barrett's Index and Presence of Intracranial Fat Prolapse in Dysthyroid Optic Neuropathy.巴雷特指数在甲状腺功能异常性视神经病变中的诊断能力及颅内脂肪脱垂情况
Clin Ophthalmol. 2022 Aug 12;16:2569-2578. doi: 10.2147/OPTH.S364987. eCollection 2022.
3
Peripapillary structural and microvascular alterations in early dysthyroid optic neuropathy.早期甲状腺功能异常性视神经病变的视乳头周围结构及微血管改变
Eye Vis (Lond). 2022 Aug 9;9(1):30. doi: 10.1186/s40662-022-00301-6.
4
Management of patients with dysthyroid optic neuropathy treated with intravenous corticosteroids and/or orbital decompression surgery.伴甲状腺功能异常性视神经病变患者的治疗：静脉用皮质类固醇激素和/或眼眶减压手术。
Graefes Arch Clin Exp Ophthalmol. 2022 Nov;260(11):3683-3691. doi: 10.1007/s00417-022-05732-4. Epub 2022 Jun 22.
5
Orbital MRI 3D Reconstruction Based on Volume Rendering in Evaluating Dysthyroid Optic Neuropathy.基于体绘制的眼眶 MRI 三维重建在甲状腺相关眼病中的评估价值。
Curr Eye Res. 2022 Aug;47(8):1179-1185. doi: 10.1080/02713683.2022.2066697. Epub 2022 May 23.
6
Insights into Current Management Strategies for Dysthyroid Optic Neuropathy: A Review.甲状腺功能异常性视神经病变当前管理策略的见解：综述
Clin Ophthalmol. 2022 Mar 18;16:841-850. doi: 10.2147/OPTH.S284609. eCollection 2022.
Zotero 插件